1Y Close · As of Aug 26, 2026
HLB Therapeutics operates in the Wholesale Trade sector.
Legal name: HLB Therapeutics Co.,Ltd.
In fiscal year 2025, HLB Therapeutics (115450) reported revenue of 69.6 billion KRW, up 26.6% from 54.9 billion KRW a year earlier.
Operating profit was -3.5 billion KRW and net income was -9.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 185.1 billion KRW, with a P/B of 1.06.
These figures can be verified in the DART filing (receipt no. 20260319001264).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 69.6B | -3.5B | -9.7B |
| 2024 | 54.9B | -7.6B | -23.5B |
| 2023 | 53.7B | -8.7B | -3.1B |
Recent Filings
Semi-Annual Report (2026.06)
Material Event Report (Early CB Retirement Decision)
Material Event Report (Capital Increase Decision)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Material Event Report (Early CB Retirement Decision) |
| 2026-08-07 | Material Event Report (Capital Increase Decision) |
| 2026-08-07 | [기재정정]주요사항보고서(전환사채권발행결정) |
| 2026-08-06 | Early CB Acquisition (Including Overseas CB) |